New treatment for leukemia
| Reference number | |
| Coordinator | Sprint Bioscience AB - Sprint Bioscience |
| Funding from Vinnova | SEK 3 804 694 |
| Project duration | December 2015 - August 2017 |
| Status | Completed |
Important results from the project
The aim of the project has been to further advance the research program and to develop potent, selective inhibitors towards the PIP4K2A protein. The inhibitors have been tested in cellular model systems with a very promising outcome.
Expected long term effects
In vitro studies on several leukemic cell lines have shown positive results where Sprint Bioscience’s compounds limit the proliferation of cancer cells, while normal blood cells aren’t affected to the same extent.
Approach and implementation
Acute myeloid leukemia is a difficult-to-treat form of cancer where there is a large unmet clinical need. We have advanced our lead compounds to more drug-like compounds with good oral bioavailability. We have also shown the potential for these compounds to become future treatments of leukemia.